Total amount: € 0,00
HOW TO ORDER
THE JOURNAL OF CARDIOVASCULAR SURGERY
A Journal on Cardiac, Vascular and Thoracic Surgery
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632
ORIGINAL ARTICLES NEW RESULTS IN THE ENDOVASCULAR MANAGEMENT OF ABDOMINAL AORTIC ANEURYSMS
The Journal of Cardiovascular Surgery 2010 August;51(4):481-91
Rationale and design of the Endurant Stent Graft Na-tural Selection Global Postmarket Registry (ENGAGE): interim analysis at 30 days of the first 180 patients enrolled
Böckler D., Fitridge R., Wolf Y., Hayes P., Silveira P. G., Numan F., Riambau V., for the Engage Investigators ✉
1 University of Heidelberg, Heidelberg, Germany;
2 Queen Elizabeth Hospital, Adelaide, Australia;
3 Sourasky Medical Center, Tel-Aviv, Israel;
4 Addenbrookes Hospital, Cambridge, Great Britain;
5 CORIS – UFSC, Florianopolis, Brazil;
6 Memorial Hospital, Istanbul, Turkey;
7 Hospital Clínico de Barcelona, Barcelona, Spain
AIM: The Endurant Stent Graft Natural Selection Global Postmarket Registry (ENGAGE) is a long-term 1200-patient multicenter prospective study initiated to augment the knowledge base (poolable and comparable) about endovascular aortic repair (EVAR) in a real-world population implanted with a single latest-generation stent graft system (Endurant). With enrollment ongoing at 80 high-volume sites, the registry has limited inclusion/exclusion criteria or procedural specification. Technical and clinical data will be reported through 5 years.
METHODS: An interim analysis was performed on investigator-reported data for the first 180 patients enrolled. These patients were asymptomatic elderly males (92.1%) with considerable comorbidities. For 47.3% of the patients, the American Society of Anesthesiologists risk class was either III or IV. The Endurant stent graft was successfully deployed in 99.4% of patients for elective treatment of abdominal aortic aneurysm.
RESULTS: Through 30 days, the rate of all-cause mortality was 1.7% (N=3), with all 3 deaths classified as procedure-related but not device-related. The rate of secondary endovascular procedures was 1.1%, and the rate of conversion to open repair was 0.6%. At postprocedure and at 30-day follow-up, there were no type I or type III endoleaks and no instances of stent graft kinking, thrombosis, or occlusion. ENGAGE represents the largest real-world registry for any single EVAR stent graft.
CONCLUSION: The interim results through 30 days of the first 180 patients enrolled are promising. Longer-term follow-up for more patients will be reported.